216 related articles for article (PubMed ID: 24531693)
21. Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex.
Piazza R; Magistroni V; Mogavero A; Andreoni F; Ambrogio C; Chiarle R; Mologni L; Bachmann PS; Lock RB; Collini P; Pelosi G; Gambacorti-Passerini C
Neoplasia; 2013 May; 15(5):511-22. PubMed ID: 23633923
[TBL] [Abstract][Full Text] [Related]
22. Systematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancer.
Yang S; Jia Y; Liu X; Winters C; Wang X; Zhang Y; Devor EJ; Hovey AM; Reyes HD; Xiao X; Xu Y; Dai D; Meng X; Thiel KW; Domann FE; Leslie KK
Oncotarget; 2014 Oct; 5(20):9783-97. PubMed ID: 25229191
[TBL] [Abstract][Full Text] [Related]
23. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer.
Cameron EE; Bachman KE; Myöhänen S; Herman JG; Baylin SB
Nat Genet; 1999 Jan; 21(1):103-7. PubMed ID: 9916800
[TBL] [Abstract][Full Text] [Related]
24. Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure.
Ghoshal K; Datta J; Majumder S; Bai S; Dong X; Parthun M; Jacob ST
Mol Cell Biol; 2002 Dec; 22(23):8302-19. PubMed ID: 12417732
[TBL] [Abstract][Full Text] [Related]
25. Methylation-mediated silencing of TMS1/ASC is accompanied by histone hypoacetylation and CpG island-localized changes in chromatin architecture.
Stimson KM; Vertino PM
J Biol Chem; 2002 Feb; 277(7):4951-8. PubMed ID: 11733524
[TBL] [Abstract][Full Text] [Related]
26. Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation.
El-Osta A; Kantharidis P; Zalcberg JR; Wolffe AP
Mol Cell Biol; 2002 Mar; 22(6):1844-57. PubMed ID: 11865062
[TBL] [Abstract][Full Text] [Related]
27. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription.
Zhang Y; Fatima N; Dufau ML
Mol Cell Biol; 2005 Sep; 25(18):7929-39. PubMed ID: 16135786
[TBL] [Abstract][Full Text] [Related]
28. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines.
Kawamoto K; Hirata H; Kikuno N; Tanaka Y; Nakagawa M; Dahiya R
Int J Cancer; 2008 Aug; 123(3):535-42. PubMed ID: 18404682
[TBL] [Abstract][Full Text] [Related]
29. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer.
Kondo Y; Shen L; Issa JP
Mol Cell Biol; 2003 Jan; 23(1):206-15. PubMed ID: 12482974
[TBL] [Abstract][Full Text] [Related]
30. Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repression.
Claus R; Fliegauf M; Stock M; Duque JA; Kolanczyk M; Lübbert M
J Leukoc Biol; 2006 Dec; 80(6):1462-72. PubMed ID: 17000900
[TBL] [Abstract][Full Text] [Related]
31. Panobinostat Enhances Growth Suppressive Effects of Progestin on Endometrial Carcinoma by Increasing Progesterone Receptor and Mitogen-Inducible Gene-6.
Ando H; Miyamoto T; Kashima H; Higuchi S; Ida K; Mvunta DH; Shiozawa T
Horm Cancer; 2017 Aug; 8(4):257-267. PubMed ID: 28516379
[TBL] [Abstract][Full Text] [Related]
32. Methylation-mediated proviral silencing is associated with MeCP2 recruitment and localized histone H3 deacetylation.
Lorincz MC; Schübeler D; Groudine M
Mol Cell Biol; 2001 Dec; 21(23):7913-22. PubMed ID: 11689684
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic regulation of GATA4 expression by histone modification in AFP-producing gastric adenocarcinoma.
Yamamura N; Kishimoto T
Exp Mol Pathol; 2012 Aug; 93(1):35-9. PubMed ID: 22472323
[TBL] [Abstract][Full Text] [Related]
34. Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs.
Deng G; Kakar S; Okudiara K; Choi E; Sleisenger MH; Kim YS
Clin Cancer Res; 2009 Mar; 15(5):1519-26. PubMed ID: 19223499
[TBL] [Abstract][Full Text] [Related]
35. Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells.
Konduri SD; Srivenugopal KS; Yanamandra N; Dinh DH; Olivero WC; Gujrati M; Foster DC; Kisiel W; Ali-Osman F; Kondraganti S; Lakka SS; Rao JS
Oncogene; 2003 Jul; 22(29):4509-16. PubMed ID: 12881707
[TBL] [Abstract][Full Text] [Related]
36. The role of DNA methylation and histone acetylation in the regulation of progesterone receptor isoforms expression in human astrocytoma cell lines.
Hansberg-Pastor V; González-Arenas A; Peña-Ortiz MA; García-Gómez E; Rodríguez-Dorantes M; Camacho-Arroyo I
Steroids; 2013 May; 78(5):500-7. PubMed ID: 23474171
[TBL] [Abstract][Full Text] [Related]
37. Histone H3 (lys-9) deacetylation is associated with transcriptional silencing of E-cadherin in colorectal cancer cell lines.
Liu Y; Hong Y; Zhao Y; Ismail TM; Wong Y; Eu KW
Cancer Invest; 2008 Jul; 26(6):575-82. PubMed ID: 18584348
[TBL] [Abstract][Full Text] [Related]
38. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells.
Lee SH; Kim J; Kim WH; Lee YM
Oncogene; 2009 Jan; 28(2):184-94. PubMed ID: 18850007
[TBL] [Abstract][Full Text] [Related]
39. Evidence of endogenous mu opioid receptor regulation by epigenetic control of the promoters.
Hwang CK; Song KY; Kim CS; Choi HS; Guo XH; Law PY; Wei LN; Loh HH
Mol Cell Biol; 2007 Jul; 27(13):4720-36. PubMed ID: 17452465
[TBL] [Abstract][Full Text] [Related]
40. Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments.
Tabolacci E; Pietrobono R; Moscato U; Oostra BA; Chiurazzi P; Neri G
Eur J Hum Genet; 2005 May; 13(5):641-8. PubMed ID: 15741991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
